arXiv:2511.13911stat.MLcs.LG2025-11NeurIPS被引 2

用置信带校准阿尔茨海默病生物标志物预测的不确定性,提升临床决策安全性。

Uncertainty-Calibrated Prediction of Randomly-Timed Biomarker Trajectories with Conformal Bands

  • 设计新型非符合度评分,实现随机随访数据下的置信带预测
  • 置信带覆盖率达标且比基线更紧凑,识别出17.5%更多高风险患者
  • 支持按人群分组的条件置信带,适用于不同临床亚群

尽管在从真实临床数据预测生物标志物轨迹方面取得进展,但预测中的不确定性带来了高风险(如误诊),限制了其在临床中的应用。为实现医疗场景中安全可靠的预测使用,本文提出一种基于置信方法的生物标志物轨迹不确定性校准预测方法,适用于患者随机随访的情况。该方法通过新颖的非符合度评分将置信预测扩展至随机时间轨迹场景,生成可保证以用户指定概率覆盖未知轨迹的预测带。我们在两项阿尔茨海默病脑部生物标志物上,对多种标准与前沿预测器进行了测试,使用真实临床研究中的神经影像数据。结果表明,本文的置信带始终达到预期覆盖率,且比基线更紧密。为进一步考虑人群异质性,我们开发了分组条件置信带,并在多个人口统计学和临床相关子人群中验证其覆盖率。此外,我们引入一种不确定性校准的风险评分,相比标准风险评分可识别出17.5%更多的高风险患者,凸显了不确定性校准在真实临床决策中的价值。代码已开源:github.com/vatass/ConformalBiomarkerTrajectories。

原文摘要 · Abstract (English)

Despite recent progress in predicting biomarker trajectories from real clinical data, uncertainty in the predictions poses high-stakes risks (e.g., misdiagnosis) that limit their clinical deployment. To enable safe and reliable use of such predictions in healthcare, we introduce a conformal method for uncertainty-calibrated prediction of biomarker trajectories resulting from randomly-timed clinical visits of patients. Our approach extends conformal prediction to the setting of randomly-timed trajectories via a novel nonconformity score that produces prediction bands guaranteed to cover the unknown biomarker trajectories with a user-prescribed probability. We apply our method across a wide range of standard and state-of-the-art predictors for two well-established brain biomarkers of Alzheimer's disease, using neuroimaging data from real clinical studies. We observe that our conformal prediction bands consistently achieve the desired coverage, while also being tighter than baseline prediction bands. To further account for population heterogeneity, we develop group-conditional conformal bands and test their coverage guarantees across various demographic and clinically relevant subpopulations. Moreover, we demonstrate the clinical utility of our conformal bands in identifying subjects at high risk of progression to Alzheimer's disease. Specifically, we introduce an uncertainty-calibrated risk score that enables the identification of 17.5% more high-risk subjects compared to standard risk scores, highlighting the value of uncertainty calibration in real-world clinical decision making. Our code is available at github.com/vatass/ConformalBiomarkerTrajectories.

生物标志物置信预测阿尔茨海默病不确定性校准

Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。